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ABSTRACT Small aquarium fish models provide useful systems not only for a better understanding of the
molecular basis of many human diseases, but also for first-line screening to identify new drug candidates.
For testing new chemical substances, current strategies mostly rely on easy to perform and efficient
embryonic screens. Cancer, however, is a disease that develops mainly during juvenile and adult stage.
Long-term treatment and the challenge to monitor changes in tumor phenotype make testing of large
chemical libraries in juvenile and adult animals cost prohibitive. We hypothesized that changes in the gene
expression profile should occur early during anti-tumor treatment, and the disease-associated transcrip-
tional change should provide a reliable readout that can be utilized to evaluate drug-induced effects. For
the current study, we used a previously established medaka melanoma model. As proof of principle, we
showed that exposure of melanoma developing fish to the drugs cisplatin or trametinib, known cancer
therapies, for a period of seven days is sufficient to detect treatment-induced changes in gene expression.
By examining whole body transcriptome responses we provide a novel route toward gene panels that
recapitulate anti-tumor outcomes thus allowing a screening of thousands of drugs using a whole-body
vertebrate model. Our results suggest that using disease-associated transcriptional change to screen
therapeutic molecules in small fish model is viable and may be applied to pre-clinical research and









Melanoma is one of the most aggressive and most deadly types of skin
cancer with an increasing incidence worldwide and a very low cure rate
once it has metastasized (Siegel et al. 2019). Despite growing awareness
of melanoma risk factors, and unique opportunities for early diagnosis,
it has become the fifthmost frequent cancer in women and the fifthmost
common cancer in men in the US (https://www.aimatmelanoma.org/
about-melanoma/melanoma-stats-facts-and-Figs/, American Cancer So-
ciety. “Cancer Facts and Figs 2018”. Atlanta: American Cancer Society;
2018.). New effective treatments like targeted therapies (BRAF- and
MEK-inhibitors) are able to increase the one-year progression free sur-
vival up to 50% (Larkin et al. 2017). However, most patients develop
resistance to those drugs after 6-9 months (Long et al. 2014). Immuno-
therapies (CTLA4- and PD1-inhbitor) are effective in 35–60% of mela-
noma patients, irrespective of the driver mutation (Gide et al. 2018;
Callahan et al. 2018). But for patients with opposing comorbidities or
high tumor load and rapid progression, immunotherapy may not be
suitable. Also, a considerable percentage of patients suffer from intoler-
able adverse effects during immunotherapy, forcing them to quit therapy
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and alter treatment strategies (Collins et al. 2016). Importantly, a large
number of patients do not benefit from any of the currently available
treatment options (Schadendorf et al. 2015). Primary or acquired resis-
tance occurs for targeted and immune therapy, leaving a direct clinical
need for at least 40–65%ofmelanoma patients (Gide et al. 2018; Callahan
et al. 2018). Hence, development of effective targeted drugs acting against
melanoma growth and progression remains indispensable.
The small aquarium fish medaka (Oryzias latipes) is a useful animal
model for biomedical research due to several advantages: fish are easy
and relatively inexpensive to maintain compared to rodent animal
models and their usage is well-accepted to study melanoma develop-
ment (Patton et al. 2010). Another advantage of fish models is their
suitability for high-throughput first-line drug screens (Van Rooijen
et al. 2017). A large number of such screening experiments have been
conducted particularly in zebrafish and have established standardized
screening technologies by exposing embryos to chemicals and moni-
toring drug effects (Oxendine et al. 2006; White et al. 2011; Colanesi
et al. 2012; Ordas et al. 2015). Apart from a stable transgenic medaka
line that was used as tumor model for in vivo testing of a known
anticancer drug (Matsuzaki et al. 2013), efficient systems to monitor
the influence of drugs on melanoma development and progression in
free swimming larvae or adult fish are still missing. Major obstacles for
developing such screens are the difficulties to evaluate possible drug-
induced effects on tumor growth in large numbers of animals and the
long times, generally weeks to months, for such changes to become
visible. Cancer is a systemic disease and develops generally at much
later stages than those accessible in embryonic screen protocols. Earlier
study has exhibited that melanoma development trajectory is deter-
mined by early stage genetic changes (Schartl et al. 2015).
We hypothesize that drug treatments should lead to early changes of
gene expression levels long before any alterations of the tumor pheno-
type (tumor load, invasion and metastasis) become obvious.
To test this hypothesis, we used the transgenic medaka melanoma
model. In these fish, malignant pigment cell tumors develop due to
expression of the xmrk driver oncogene, which is a constitutively acti-
vated mutant version of the epidermal growth factor (Egf) receptor
under control of the medaka melanocyte-specific mitfa promoter
(Schartl et al. 2010). In these transgenic fish, melanoma development
initiates in larvae and progresses further in juvenile and adult stages.
The tumors are highly similar on the histopathological and molecular
level to the native Xiphophorus melanoma system from which the
oncogene is derived. Importantly, gene expression studies showed that
these xmrk-induced fish melanomas are comparable to human tumors
(Schartl et al. 2012; Schartl et al. 2015; Klotz et al. 2018; Lu et al. 2018)
and thus provide suitable models for experimental studies. Using mel-
anoma-effective drugs cisplatin and trametinib, we performed short-
term exposures of juvenile medaka with developing melanoma, and
compared the modulated gene expression profiles to similarly treated
healthy wild-typemedaka. Herein, we detail changes in gene expression
that can be monitored from whole-fish total RNA extraction after
short-term drug exposures. Our previous study showed that transcrip-
tional changes induced by a disease-driving oncogene (i.e., xmrk) could
collectively serve as a transcriptional phenotype for disease diagnosis,
and can be used for pilot drug screening. However, different classes of
medicine (e.g., kinase inhibitor, hormone) act in different mechanisms
and may lead to different transcriptional changes. Therefore, this man-
uscript aims to test whether small molecule treatment can lead early to
transcriptional changes. These results can be used to establish treat-
ment specific transcriptional disease signatures (TTDS) to develop high
throughput chemical screens for substances with potential for mela-
noma therapeutics.
MATERIAL AND METHODS
Experimental Animals and fish maintenance
Wild-type (wt, inbred strain Carbio) and transgenic (tg) medaka of the
Tg(mitf:xmrk) strain on the Carbio genetic background (Schartl et al.
2010) were used for this study. Fish were maintained under standard
conditions in the aquarium facility of the Biocenter at the University of
Wuerzburg according to local animal welfare laws and guidelines and
with the authorization (55.2 – 2531.01 – 40/14) of the Veterinary Office
of the District Government of Lower Franconia, Germany, in accor-
dance with German Animal Protection Laws.
Compound treatment
Cisplatin (Merck KGaA, Darmstadt, Germany) and trametinib (Selleck
Chemicals, Houston, USA) and their corresponding solvents were used
for treatment. Cisplatin was administered at a concentration of 70 mM
(solvent 0.9% NaCl), and trametinib was used at a concentration of
20 nM (solvent 1% DMSO). Fish between 3-5 weeks of age and a
standard length of 10 6 2 mm were exposed to these substances over
seven days. Fish were divided into control (solvent-treated) and drug-
treated groups andmaintained in small petri dishes in a volume of 20ml
conditioned tank water at 23 at 12 hr/12 hr light/dark cycle. After daily
feeding with Artemia naupliae, the water was changed and drugs or
solvents alone were freshly added. For RNA sequencing, 10 transgenic
(tg) and 5 wild-type (wt) fish each treated with cisplatin or trametinib
and 5 wt and 5 tg fish that were treated with solvent were used.
RNA-sequencing (RNA-seq)
Total RNA from the whole fish body was isolated using TRIzol Reagent
(Thermo Fisher Scientific, Waltham, USA) according to the supplier’s
recommendation. RNA Integrity Number (RIN) was assessed using an
Agilent 2100 Electrophoresis Bioanalyzer Instrument G2939A (Agilent
Technologies, Böblingen, Germany). Only samples with RIN values.
8 were used for sequencing. RNA sequencing libraries were produced
according to the standard IlluminamRNA library preparation protocol
(www.illumina.com; Illumina Inc., San Diego, CA, U.S.A.) and se-
quenced at 150 bp paired end reads with a sequencing depth of approx.
72 million reads per sample.
RNA-seq validation by quantitative real-time PCR (qRT-
PCR)
Whole treated and solvent-treated wt and tg three to five week old fish
(n= 5 or 10 in each group) were used to extract total RNA using TRIzol
Reagent (Thermo Fisher Scientific, Waltham, USA) according to the
supplier’s recommendation. The RNA (2 mM) was treated with DNase
and transcribed into cDNA using the RevertAid First Strand cDNA
Synthesis kit (Thermo Fisher Scientific, Waltham, USA) with random
hexamer primers in accordance with the manufacturer’s instructions.
This cDNA was used as a template for qRT-PCR in a 25 ml volume
SYBR Green reagent containing mastermix and was analyzed in trip-
licate. Amplifications were carried out in a Mastercycler ep realplex2
(Eppendorf, Hamburg, Germany) with cycling parameters as follows:
95 for 5 min, followed by 40 cycles of 95 for 30 s, 60 for 30 s and 72
for 20 s. For qRT-PCR-Primer sequences, see Table S1. Quantitative
RT-PCR data were quantified by the delta Ct method (Simpson et al.
2000) and the expression of each gene of interest was normalized to
the housekeeping gene ef1a1 (elongation factor 1 alpha 1). Statistical
significance of different mRNA expression levels was checked using
Wilcoxon-Mann-Whitney U-test or Student’s t-test depending on the
size and distribution of the samples. Student’s t-test was used for nor-
mally distributed data with a sample size larger than nine. Data without
2268 | B. Klotz et al.
normal distribution or with a sample size less than nine were analyzed
using the non-parametric Wilcoxon-Mann-Whitney U-test. A selec-
tion of differentially expressed genes was validated by qRT-PCR
and confirmed the direction of regulation from the RNA-seq data
(Table S2).
Bioinformatics, statistical analysis and differential
gene expression
Paired end sequences were trimmed using Trimmomatic (-phred33)
with the TruSeq3-PE.fa as adapter file. Sequences were aligned to the
medaka genome (ASM223467v1) using the STAR RNA-seq aligner
(Dobin et al. 2013) and the genes were quantified by RSEM
(Li and Dewey 2011). Differential expression was calculated by
the R/Bioconductor package ‘DESeq2’ (Love et al. 2014). For corre-
spondence analysis, the R/Bioconductor package ‘made4’ was used.
Genes were considered to be differentially expressed in comparison to
the corresponding solvent-treated wt or tg fish, if they had a log2 fold
change (log2FC) ,-1 or . +1 and a p-value , 0.05.
Pathway and transcription regulator enrichment
First, we focused on genes that were up- and downregulated (log2FC
,-1 or . +1, p-value , 0.05) in one of the following groups: a) in
both cisplatin-treated wt and tg fish; b) in cisplatin-treated wt fish
vs. solvent-(NaCl)-treated wt fish; c) in cisplatin-treated tg fish vs.
solvent-(NaCl)-treated tg fish; d) expressed in both trametinib-
treated wt and tg fish; e) in trametinib-treated wt fish vs. solvent-
(DMSO)-treated wt fish and f) in trametinib-treated tg fish vs.
DMSO-treated tg fish. To enable further functional analysis of
anti-melanoma drug-treated wt and tg whole body transcriptomes,
differentially expressed medaka genes were matched to their human
orthologs using Ensembl BioMart (http://www.ensembl.org/biomart/
martview/662764dc0a1ef355f59d8c648d5196be), the DAVID Gene
Accession Conversion Tool (https://david.ncifcrf.gov/conversion.jsp)
and manual annotation after BLASTN searches https://www.ensem-
bl.org/Multi/Tools/Blast?db=core) for genes that were not annotated
in the medaka genome. WebGestalt (http://www.webgestalt.org/
2013/option.php) and DAVID (https://david.ncifcrf.gov/) functional
enrichment analysis web tools were used for functional classifica-
tion using default settings. Some of the over-represented KEGG path-
ways in Trametinib-treated tg samples were selected and colored
with the Search&Color Pathway tool (https://www.genome.jp/kegg/
tool/map_pathway2.html).
Data availability
All data necessary to confirm the conclusions of the current article are
represented fullywithin thismanuscript and the supplementalmaterial.
Supplemental material available at FigShare: https://doi.org/10.25387/
g3.8075777.
RESULTS AND DISCUSSION
The intention of the current study was to uncover treatment-induced
gene expression changes in the tg medaka melanoma model (Schartl
et al. 2010) compared to healthy fish. Two established anti-cancer
drugs, cisplatin and trametinib, were administered to juvenile medaka
over seven days to investigate drug-specific effects on single gene ex-
pression patterns and genetic pathways compared to solvent-treated
control fish. The MEK-inhibitor trametinib and the cytostatic drug
cisplatin, which inhibits DNA replication, differ in their mode of mo-
lecular action. Activation of the Ras-Raf-MEK-ERK (MAPK) pathway
is a common feature of most human melanomas and is also the driver
signaling pathway in the tg melanoma medaka (Meierjohann and
Schartl 2006; Wellbrock and Arozarena 2016). Both substances are
approved for clinical application. Cisplatin is effective against different
types of cancers, including melanoma. It is a platinum-based chemo-
therapeutic drug, which crosslinks DNA and thereby interferes with
DNA replication and mitosis and induces pro-apoptotic effects (Wang
and Lippard 2005; Kelland 2007).
Whole-body gene expression profiles from cisplatin (70 mM) and
trametinib (20 nM) treated juvenile (3-5 weeks old) healthy (wt) and
early-stage melanoma (tg) fish were compared to solvent-treated fish
(wt and tg). Differentially expressed genes were used to define specific
signatures of cisplatin- or trametinib-treatedwt and tg fish compared to
controls. Earlier gene expression studies revealed the feasibility to ex-
tract melanoma-specific gene expression patterns from transcriptomic
data based on whole fish body RNA isolates and the response of the
juvenile fish (`host response’) to the initial melanoma stage (Schartl
et al. 2015; Klotz et al. 2018). In this study RNA based gene expression
signatures of similar and different patterns for gene expression in treat-
ed wt and tgmedaka were established. `Similarities` between treated wt
and tg fish were interpreted as global drug-induced effects that point to
drug-induced side effects, whereas `differences` between treated wt and
tg fish were considered to identify drug-specific response in disease
(drug-specific treatment signature).
Cisplatin
The differential expression analysis of cisplatin-treated medaka com-
pared to solvent-(NaCl)-treated medaka identified 655 genes that were
differentially expressed comparing treated to untreated wt fish (n = 5)
and 75 genes that were differentially expressed comparing treated to
untreated tg fish (n = 10). We identified 65 up- and 590 downregulated
genes exclusively in wt fish and 36 up- and 39 downregulated genes
exclusively in tgmedaka (Figure 1).Wematched differentially regulated
medaka genes to their human orthologs to enable further functional
analysis. Of the 655 differentially regulated genes in wt medaka,
441 (29 upregulated, 412 downregulated) matched to human gene
annotation and 61 (25 up, 36 down) of 75 differentially regulated genes
in tg fish matched human orthologs (Figure 1).
Commonly regulated genes in cisplatin-treated wt and
tg fish
Commonly up- anddown-regulated genes in cisplatin-treatedwt and tg
fish are considered as general drug-induced effects representingpossibly
unwanted or adverse side effects. We identified 11 commonly upregu-
lated and seven commonly downregulated genes. Three (fabp1,mdm2,
slc19a3) of 11 commonly upregulated and one (kcnj1) of seven com-
monly downregulated genes in juvenile cisplatin-treated wt and tg
medaka corresponded to human orthologs (Figure 1), and information
about their function is available to allow for biological inference of
cancer influences.
Fatty acid binding protein 1 (fabp1) is highly expressed in hepatocytes
but is also found in other cell types and tissues (Iseki et al. 1990; Pelsers
et al. 2003). FABP1 is involved in the cellular uptake, transport and
metabolism of fatty acids as well as in regulation of gene expression
and cell differentiation (Wang et al. 2015). Cisplatin-injected sv129 mice
showed increased fabp1 mRNA expression levels three days after injec-
tion in kidney tissue compared to saline-treated mice (Negishi et al.
2007). At the protein level, cisplatin treatment of rat primary hepatocytes
over 24 hr induced FABP1 expression (Cho et al. 2012). These findings
are in accordance with the enhanced fabp1 expression we found in
cisplatin-treated medaka. Human liver cells transfected with FABP1
cDNA showed higher resistance toward Acetaminophen-induced
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hepatotoxicity compared to empty vector transfected cells (Gong et al.
2014) and this result was explained by an antioxidant function of FABP1
expressing cells. The cisplatin-induced increase of fabp1 expression in wt
and tg medaka may be also an organismal strategy to fight the cisplatin-
triggered increase of reactive oxygen species levels.
Mdm2 (encoded bymdm2) is an E3 ubiquitin ligase localized in the
nucleus that acts as an inhibitor of p53 (tumor protein p53) through
the induction of p53 protein degradation. DNA-damaging agents like
cisplatin activate p53, which in turn upregulates MDM2 (Moll and
Petrenko 2003; Basu and Krishnamurthy 2010). This finding is
reflected in cisplatin-treated murine testicular cancer cell lines showing
increased expression levels of Mdm2 mRNA (Di Pietro et al. 2012).
We interpret the increased expression of mdm2 as a general cisplatin-
induced DNA damage response.
slc19a3 (solute carrier family 19, member 3) encodes a thiamine
transporter (Ganapathy et al. 2004) and therefore its upregulation
might reflect its function as transporter for drug absorption, elimina-
tion or possibly mediating chemosensitivity.
The kcnj1 (potassium voltage-gated channel subfamily J member 1)
gene was identified as the only commonly downregulated gene in cis-
platin-treated wt and tg fish. This ATP-dependent potassium channel is
important for the homeostasis of potassium channels and is predom-
inantly found in kidney tissues of rats and humans (Nüsing et al. 2005;
Welling andHo 2009). It is also expressed in cells and organs associated
with osmoregulation in developing zebrafish embryos (Abbas et al.
2011) but has not been reported so far to be regulated in response to
cisplatin treatment.
Besides the commonly regulated genes in wt and tg medaka, which
represent the side effects of the drug, we also found genes that were only
affected by the drug treatment in wt fish (see Supplemental Note 1).
Cisplatin-induced specific effects in juvenile tg medaka
Many of the enriched GO terms in cisplatin-treated tg melanoma
medaka compared to vehicle-treated tg melanoma controls are associ-
ated with pigmentation and cellular transport activity. All GO terms
comprise one of the following three groups of upregulated genes (Table
S3): alkaline phosphatases (alpi, alpp, alppl2 (alkaline phosphatase, in-
testinal, placental and placental-like 2)), members of the solute carrier
family (slc3a1, slc6a19, slc15a1, slc26a6) as well as the bloc1 genes
(bloc1s6 (biogenesis of lysosomal organelles complex-1, subunit 6, pal-
lidin), bloc1s4 (biogenesis of lysosomal organelles complex-1, subunit 4,
cappuccino), bloc1s1 (biogenesis of lysosomal organelles complex-1,
subunit 1)). These bloc1 genes encode proteins forming subunits of
the cytosolic protein complex BLOC-1 (biogenesis of lysosome‐related
organelles complex-1), which plays an important role in the formation
of specialized organelles of the endosomal-lysosomal system for exam-
ple melanosomes (Starcevic and Dell’angelica 2004). This result is in
accordance with the tumorigenic phenotype of the tgmedaka caused by
the expression of xmrk triggering hyperpigmentation of the skin al-
ready some days after hatching and the formation of pigment cell
tumors as described earlier (Schartl et al. 2015; Klotz et al. 2018). We
did not observe any phenotypic changes in the cisplatin-treated tg
medaka (data not shown). It is interesting to note that several of the
genes and enrichedGO terms that are affected by the treatment are part
of the melanomatous fish specific expression profile identified in two
earlier studies (Schartl et al. 2015; Klotz et al. 2018). In addition, a set of
upregulated genes and enriched GO terms appear as “early cisplatin-
induced gene expression change”. Untreated tg fish from the two earlier
studies showed an upregulation of tyrp1 (tyrosinase-related protein 1),
pmel (premelanosome protein) or tyr (tyrosinase), all known as typical
melanin synthesis and pigmentation associated genes (Schartl et al.
2015; Ainger et al. 2017; Klotz et al. 2018). These genes were not
upregulated in the cisplatin-treated tg fish compared to solvent-treated
tg fish, but we detected an enhanced expression of the BLOC genes
indicating a drug effect on melanoma on the gene expression level.
Additionally, the cisplatin-treated tg fish showed an enrichment of
the GO terms `melanosome organization’ (GO:0032438) and `pigment
granule organization` (GO:0048753) displaying potentially cisplatin-
affected pigmentation-associated transformation processes in the
treated medaka (Table S3).
The upregulated genes of the solute carrier family in many
enriched GO terms (e.g., `secondary active transmembrane trans-
porter activity` (GO:0015291) or `solute:cation symporter activity`
(GO:0015294)) (Table S3) are of special interest because they function
as membrane influx or also bi-directional transporters mediating the
uptake, distribution, metabolization and elimination of substrates like
glucose, amino acids, metals and most importantly (anti-cancer)
drugs (He et al. 2009; Li and Shu 2014). Solute carriers have profound
influence on drug efficacy. We noted upregulated expression of the
genes slc3a1 (solute carrier family 3 (cystine, dibasic and neutral
amino acid transporters, activator of cystine, dibasic and neutral
amino acid transport), member 1), slc6a19 (solute carrier family
6 (neutral amino acid transporter), member 19), slc26a6 (solute car-
rier family 26, member 6) and slc15a1 (solute carrier family 15 (oli-
gopeptide transporter), member 1) in the cisplatin-treated melanoma
medaka. We assume that the upregulated expression of these genes is
a result of absorbing, metabolizing and eliminating processes due to
cisplatin treatment (Li and Shu 2014).
Among the downregulated genes, we identified an enrichment of 27
GO terms including many cell cycle associated GO terms (e.g., `mitotic
cell cycle` (GO:0000278), `cell cycle process` (GO:0022402)) as well as
GO terms related to cell biology and cellular processes in general (e.g.,
`cytoskeletal part` (GO:0044430), `cytosol`(GO:0005829)) (Table S4).
racgap1 (Rac GTPase activating protein 1), a member of the family
of Rho GTPase-activating proteins (Touré et al. 1998; Jantsch-Plunger
et al. 2000), is one of the downregulated genes included in the enriched
Figure 1 The Venn-diagram represents differentially
expressed genes (in brackets: human orthologs) in
cisplatin-treated wild-type and transgenic medaka.
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GO terms. It is important for the induction and regulation of cytokinesis,
cellular growth and differentiation but also for transformation and me-
tastasis (Hirose et al. 2001; Kitamura et al. 2001; Mi et al. 2016). Its
expression is elevated in several cancer types like breast (Pliarchopoulou
et al. 2013), gastric (Saigusa et al. 2015) or lung cancer (Liang et al. 2013)
where high RACGAP1 expression is accompanied by greater aggressive-
ness and invasion of tumors as well as poor prognosis for patients. These
findings provide strong evidence for a cisplatin-caused suppression of the
proliferative and transcriptionally active state of themelanoma tumor in tg
fish samples.
Ataxia telangiectasia mutated (atm) was also downregulated. A
mutated version of the ATM gene causes ataxia telangiectasia, a disease
causing increased susceptibility to cancer (Savitsky et al. 1995). ATM
encodes a kinase important for the repair of DNAdouble-strand breaks
(Shiloh 2003). It was reported that low ATM expression and poor
survival rate correlate in cancer patients (Knappskog et al. 2012;
Feng et al. 2015; Petersen et al. 2017). The downregulation of atm in
the cisplatin-treated tg samples would result in a compromised repair
of DNA leading to an already earlier described increase of cisplatin-
induced apoptosis (Colton et al. 2006).
Twodownregulated genes, gmppb (GDP-mannosepyrophosphorylase
B) and gmds (GDP-mannose 4,6-dehydratase) are members of the
enriched KEGG pathways `fructose and mannose metabolism`
(ID:00051) and `amino sugar and nucleotide sugar metabolism`
(ID:01100) (Table S5). The Gmppb protein (Noda et al. 2003) is impor-
tant for the production of N-linked oligosaccharides (Ning and Elbein
2000) and the inhibition of theN-linked oligosaccharides leads to reduced
invasion of tumor cells in vitro (Dennis 1991). Gmds catalyzes the first
step of the de-novo synthesis of GDP-fucose, which is an essential com-
ponent of cellular fucosylation (Becker and Lowe 2003). Deregulated
fucosylation is associated with different cancer types (e.g., hepatocellular
or ovarian carcinoma) (Noda et al. 2003; Escrevente et al. 2006; Wei et al.
2018). GDMS was upregulated in tissues from lung adenocarcinoma
patients and its knockdown induced cell cycle arrest and apoptosis in
human lung adenocarcinoma cell lines (A549, H1299) as well as an
inhibited tumor growth in a xenograft mice model of lung adenocarci-
noma (Wei et al. 2018). Both enriched KEGG pathways are linked to
carbohydrate metabolism and its alteration is typical for cancer cells re-
quiring high energy production for their uncontrolled cellular prolifera-
tion. Downregulation of these two-carbohydratemetabolism related genes
proposes that cisplatin treatment ofmelanomafish has an inhibiting effect
on carbohydratemetabolism and its energy producing steps and therefore
may suppress uncontrolled cell growth. This may be in concert with the
upregulation of fatty acid binding protein as a shift from carbohydrate to
lipid metabolism as a primary energy source.
Wealsoobserved cisplatin-induced expression changesofmembers of
the alkalinephosphatase family (alpi,alpp,alppl2). Several studies indicate
elevated alkaline phosphatase levels as evidence for hepatobiliary diseases
(Moss 1989; Giannini et al. 2005; Lala and Minter 2018). The upregula-
tion of alpi, alpp and alppl2 can be a direct result of the metabolization of
the absorbed drug cisplatin in the tgmedaka. This could be interpreted as
adverse effects of the drug treatment.
Trametinib
The differential expression analysis of trametinib-treated medaka com-
pared to solvent-(DMSO)-treated medaka resulted in 109 up- and
126 downregulated genes exclusively in wt fish (n = 5) and in 125 dif-
ferentially expressed genes exclusively in tg fish (62 upregulated,
60downregulated) (n=10).A total of 141 of 235 differentially expressed
genes in trametinib-treated wt fish matched to human orthologs
(75 upregulated, 66 downregulated). In tgmedaka, 29 of 62 upregulated
genes and 40 of 60 downregulated genes matched to their human gene
orthologs (Figure 2).
Commonly expressed genes in trametinib-treated wt
and tg fish
Comparing trametinib-induced specific expression changes in wt and tg
medaka, 69 of the 117 commonly upregulated genes and 17 of the
34commonlydownregulatedgenesmatched tohumanorthologs (Figure
2). Trametinib-induced effects common to both wt and tg fish included
upregulation of immune system associated genes and genes related to
cellular transporter activity, as well as oxidoreductase activity (Table S6).
Upregulated immune associated genes could be a general response of the
fish to the trametinib-induced pro-inflammatory and pro-apoptotic ef-
fects described by Lulli et al. (2017). An attempt to eliminate this drug
may be reflected by the enhanced expression of the drug metabolizing
enzymes cyp24a1 (cytochrome P450, family 24, subfamily A, polypep-
tide 1) and cyp21a2 (cytochrome P450, family 21, subfamily A, poly-
peptide 2). The cytochrome P450 enzyme family plays a crucial role in
the biotransformation and elimination of drugs (Ogu and Maxa 2000;
Mittal et al. 2015). Furthermore, trametinib also induced complement
system genes, a hallmark of inflammatory processes (Frank and Fries
1991; Kirschfink 1997; Markiewski and Lambris 2007) that was not
observed in the DMSO-treated wt and tg medaka. The activation of
the complement system, which is normally triggered by pathogens to
combat infections (Dunkelberger and Song 2010), may be involved in
eliminating damaged and apoptotic cells (Noris and Remuzzi 2013).
Our data suggest that trametinib activates inflammatory and immune
system associated processes in wt and tg medaka.
Trametinib induced a downregulation of several genes with GO
terms `regulation of tissue remodeling` (GO:0034103), `motor neuron
axon guidance` (GO:0008045) or `regulation of cell-substrate junction
assembly` (GO:0090109) inwt and tgfish (Table S7). These include etv4
(ets variant 4), grem1 (gremlin 1) and hrg (Histidine Rich Glycopro-
tein). The etv4 gene encodes a member of the ETS transcription factor
Figure 2 The Venn-diagram represents differentially
expressed genes (in brackets: human orthologs) in
trametinib-treated wild-type and transgenic medaka.
Volume 9 July 2019 | Expression Profiles of Medaka Melanomas | 2271
family, which is involved in organ development, cell proliferation and
tumorigenesis (Chotteau-Lelièvre et al. 1997; Dumortier et al. 2018).
Increased expression of ETV4 was reported in several types of cancer
(e.g., breast (Yuan et al. 2014; Dumortier et al. 2018) and prostate cancer
(Pellecchia et al. 2012; Qi et al. 2015) and esophageal squamous cell
carcinoma (Qi et al. 2015)). The trametinib-induced downregulation of
etv4 in tg fish is in accordance with the finding that trametinib treatment
leads to a reduced expression of ETV4 in pancreatic cancer cell lines
(Wang et al. 2017). Trametinib treatment resulted in a much stronger
downregulation of etv4 in melanoma-bearing tg medaka than in wt fish.
We conclude that the trametinib-induced downregulation of etv4 func-
tions inhibits cell proliferation in wt and tg fish, because it has been
shown that decreased ETV4 expression in malignant cells is accompa-
nied by reduced cell growth and migration (Pellecchia et al. 2012).
The member of the BMP (bone morphogenic protein) antagonist
family grem1 (gremlin 1) (Church et al. 2015) is also downregulated in
trametinib-treated wt and tg medaka. Grem1 is involved in embryonic
development (Costello et al. 2010) but it was also found to be expressed
in stromal cells of human tumorigenic tissues contributing to a tumor
microenvironment regulated growth and invasion of cancer (Sneddon
et al. 2006). Moreover, increased GREM1 mRNA levels were observed
in several different cancer types (e.g., lung, colon, breast or pancreas)
(Namkoong et al. 2006). With the genes grem1 and etv4, we identified
two genes involved in developmental and carcinogenic processes and
our data show that trametinib targets the expression of such potential
carcinogenic candidate genes irrespective of whether its administration
occurred in a tumor situation or not, indicating that this drug exerts an
inhibitory influence on developmental and proliferative states in cells
and organisms.
Besides the commonly regulated genes in wt and tg medaka we also
found genes that were only affected by the drug treatment inwt fish (see
Supplemental Note 2).
Trametinib-induced effects on juvenile tg medaka
Trametinib treatment changed the expression profile of the tg fish
compared to the solvent-treated tg medaka as illustrated by a high
number of enrichedGO terms andKEGGpathways (Table S8, S9, Table
S10, Table S11). Genes of the enriched `MAPK (mitogen-activated
protein kinase) signaling pathway` are up- or down-regulated. This
finding is of particular interest because: 1) an activatedMAPK signaling
pathway is often observed in human cancers including melanoma
(Davies et al. 2002; Ohren et al. 2004; Dhillon et al. 2007; Inamdar
et al. 2010) and 2) the trametinib-induced inhibition of the MEK1/2
protein kinases leading to a reduction of downstream MAPK signaling
and cell growth of tumor cells can be seen as evidence for the drug
effectiveness in the tg melanoma fish. Upon trametinib treatment
gadd45g (growth arrest and DNA-damage-inducible, gamma) and
mknk2 (MAP kinase interacting serine/threonine kinase 2) are upregu-
lated, while dusp4, dusp6 (dual specificity phosphatase 4, 6) and nr4a1
(nur77, nuclear receptor subfamily 4, group A, member 1) are down-
regulated in the tg fish. The tumor suppressor gene gadd45g is a mem-
ber of the GADD45 family and plays an important role in cell cycle
arrest (Ying et al. 2005) and its overexpression has an inhibitory func-
tion on the proliferation of transformed cells. Downregulation of
gadd45g has been described in many different tumor cell lines (Zhan
et al. 1994; Vairapandi et al. 2002; Ying et al. 2005; Zerbini and Lib-
ermann 2005). The trametinib-treated tg samples showed an enhanced
gadd45g expression level implying a trametinib-induced transition
from a melanogenic expression profile toward a less cancerogenic
and more normal expression profile. The melanogenic profile is still
visible by the expression of dusp4, dusp6 and nr4a1, which is, however,
strongly diminished, as expected if the drug were normalizing the tran-
scriptomic disease phenotype. Interestingly, Tamura et al. (2012)
described an enhanced expression of the GADD45 proteins due to
anti-cancer drugs like Genistein or Trichostatin A along with a growth
arrest in different tumor cell lines. These findings are in line with the
increased expression of gadd45g in the trametinib-treated medaka in
the current study. Besides an upregulation, the MAPK cascade in the
trametinib-treated samples also shows a number of downregulated
genes, thus providing evidence for the efficacy of the trametinib treat-
ment: we identified flt4 (fms-related tyrosine kinase 4), nr4a1 and
members of the dusp family as downregulated genes within the MAPK
signaling pathway, which are located at main nodes or directly influ-
encing important members of this signaling cascade. Flt4, a tyrosine
kinase receptor for the ligand VEGF-C (vascular endothelial growth
factors C), is positioned at the top of theMAPK signaling cascade and it
is known to be expressed on high levels in several human cancer types
including non-small cell lung cancer tissues from patients (Li et al.
2006), advanced-stage specimens of prostate cancer (Kaushal et al.
2005), head and neck tumors (Neuchrist et al. 2003) or sera samples
from patients suffering from metastatic melanoma (Mouawad et al.
2009). These reports indicate a connection between enhanced flt4 ex-
pression and tumor development and progression. Furthermore, FLT4
is involved in sprouting angiogenesis and it is highly expressed in the
microvasculature of tumors and wounds (Valtola et al. 1999; Paavonen
et al. 2000). Antibody-mediated blocking of FLT4 signaling leads to
reduced blood vessel sprouting, vessel branching, and endothelial cell
growth in mouse angiogenesis models (Tammela et al. 2008). Trans-
ferring these findings to our data, the trametinib-induced decrease
of flt4 expression might result in decreased development of tumor-
supporting blood vessels in trametinib-treated tg medaka.
Dusp4 and Dusp6 dephosphorylate kinases leading to an inactiva-
tion of theMAPK familymembers ERK, JNKandp38, which are closely
associated with processes of cellular proliferation and differentiation,
and therefore, act as negative regulators ofMAPK signaling (Clark et al.
2008; Huang and Tan 2012). The downregulation of both genes in our
treatments may be reconciled by the finding that BRAF or MEK in-
hibition significantly reduces expression of dusp4, dusp6, spry2 and
spry4 (Sprouty RTK Signaling Antagonist 2, 4) (Pratilas et al. 2009).
Beside the dusp genes, also a reduced expression of spry4 was observed
in the trametinib-treated fish. The Ras/ERK pathway induces expres-
sion of SPRY and dysregulation of SPRY genes occurs in many tumor
types e.g., cancer of the breast (Faratian et al. 2011; Vanas et al. 2014)
and liver (Sirivatanauksorn et al. 2012). Reports also describe the upre-
gulation of SPRY2 expression in melanoma cells with mutated B-Raf
or N-Ras compared to melanomas with wild-type B-Raf probably due
to theenhanced expression or activity of p-ERK in these cells
(Tsavachidou et al. 2004; Bloethner et al. 2005). Therefore, the down-
regulation of spry4 in trametinib-treated tg medaka could be a direct
consequence of the reduced expression of flt4 localized upstream in the
MAPK signaling cascade.
The nuclear receptor nr4a1 is an immediate-early response gene in-
volved in cell proliferation and differentiation. We interpret the down-
regulation of nr4a1 in trametinib-treated samples to provide further
evidence for the transition of a transformed phenotype toward a less
malignant melanoma phenotype after trametinib treatment because high
nr4a1 expression has often been detected in tumorigenic tissues and cells
or solid tumors (Cho et al. 2007; Cho et al. 2010; Lee et al. 2010; Lee et al.
2014; To et al. 2014). Ectopic expression of NR4A1 promotes cell cycle
progression and proliferation in lung cancer cells (Kolluri et al. 2003), at
the same timeNR4A1 repression has an inhibitory effect on the transition
phenotype of several cancer cell types by promoting the induction of
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apoptosis (Ke et al. 2004). However, stable knockdown of NR4A1 by
RNA interference conferred resistance of melanoma cells to apoptosis
induced by chemotherapeutic drugs (e.g., Cisplatin) (Yu et al. 2007).
Therefore, the reduced nr4a1 expression as a result of the trametinib
treatment could also be interpreted as adverse effect of the drug treatment
in the tg medaka. But there is also a report that the inhibition of MAPK
signaling in melanoma cells either by BRAF knockdown or by the usage
of the MEK1/2 specific inhibitors UO126 and PD98059 leads to a clear
reduction of the NR4A1 expression (Smith et al. 2011).
Short overview of regulated evolutionarily conserved
medaka genes, which are also differentially expressed
in diverse human cancers
Differentially expressed evolutionarily conserved medaka genes, which
wereuncovered inCisplatin-andTrametinib-treatedmedakacompared
tosolvent-treatedmedaka (see3.1. and3.2.)were screened if theyarealso
regulated in humanmelanomaand inother types of human cancers or if
theyare regulated inamoregeneral context of differenthumansignaling
pathways. For identification of these consistently regulated genes the
Gene Set Enrichment Analysis (GSEA) software (http://software.broa-
dinstitute.org/gsea/index.jsp) were used (http://software.broadinstitu-
te.org/gsea/index.jsp).
In the context of melanoma and melanoma associated pathways,
10 differentially expressed medaka genes uncovered in the above
presented different expression profiles (see 3.1.1., 3.1.2., 3.2.1. and
3.2.2.) were identified to be also regulated in human melanoma and
melanoma associated pathways, in particular the genesDUSP4,DUSP6,
GADD45G, IL1R2 (interleukin-1 receptor type 2),MAP3K8 (mitogen-
activated protein kinase kinase kinase 8), MDM2, MKNK2, NR4A1,
PMM1 and TNF (tumor necrosis factor) (Table S12). Particularly,
the important MAPK pathway, which is a central regulator of mela-
noma growth showed overlapping features. The WNT/b-catenin sig-
naling pathway, which is often regulated in advanced melanoma, was
not found to be regulated in our study, probably due to the early stage of
melanoma development represented by our model.
A selection of human gene sets of different cancer types was
compared with regulated medaka genes. In particular, comparison to
neural tumors revealed eight consistently regulated genes (ABCC3,
CUTC, ETV4, MDM2, PHF23, PTAFR, RNF135, SHC3) (Table S13).
Differentially expressed medaka genes were also compared to human
gene sets and signaling pathways,which are not primarily cancer pathways
but maybe associated with cancer-related processes (e.g., apoptosis, in-
flammation, DNA repair, immune-system associated processes) could be
detected (Table S14).
CONCLUSIONS
The treatment of juvenile medaka with anti-cancer drugs over a short
period of seven days led to considerable changes of the gene expression
signature. Through comparisons with non-treated and sham treated fish,
we could separate drug-induced side-effects from effects specific for the
melanoma fish. For instance, the upregulation of several members of the
solute carrier family in cisplatin-treated tg fish was interpreted as a
reflection of the general drug-metabolizing processes. Drug-induced ex-
pression changes in cisplatin- and trametinib-treated medaka define
treatment-induced expression changes in the TTDS. At the same time,
the downregulation of racgap1, gmppb and gmds provide strong evidence
for a cisplatin-induced suppression of the proliferative and transcription-
ally active state of themelanoma tumors and their uncontrolled growth in
tg medaka. Trametinib treatment elicited pro-inflammatory and pro-
apoptotic expression changes as evidenced by the enhanced expression
of genes of the complement system in both wt and tg fish. Reduced
expression of genes associated with cellular processes and inhibited pro-
tein synthesis was observed in trametinib-treated wt medaka. Treated tg
fish differentially expressed several genes enriched in the `MAPK signal-
ing pathway` suggesting a shift from the transformed phenotype to a less
malignant phenotype of the tg medaka. We identified only one common
gene in tgmedaka for both treatments. This result can be expected because
these two drugs affect different pathways in cancer cells and their highly
complex expression networks. The current study was a first line drug
screen important to prove the feasibility of anti-cancer drug screens in
the transgenic medaka model. For further determination of a set of com-
mon TTDS genes, additional studies are needed. These data will be useful
to refine the current TDS set of 365 genes that has been shown to be a
useful readout for drug treatment in the transgenic medaka melanoma
model.
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